SCHEMBL29467142

SCHEMBL29467142

O=C1CCCc2cc(F)cc(F)c2N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 2/20 0.41
▸ TGM2 P21980 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KIF11 P52732 3/20 0.40
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ SRD5A1 P18405 2/20 0.36
▸ LMNA P02545 2/20 0.35
▸ METAP2 P50579 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GRIN2D O15399 1/20 0.33
▸ GRIN3B O60391 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2A Q12879 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ GRIN2C Q14957 1/20 0.33
▸ GRIN3A Q8TCU5 1/20 0.33
▸ DDB1 Q16531 1/20 0.33
▸ RIPK1 Q13546 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15964547 1.00 CRBN (0.41) CRBNTGM2MAPTKIF11MEN1
SCHEMBL4779861 0.89 KIF11 (0.48) CRBNTGM2KIF11KMT2ANPC1
SCHEMBL15956938 0.83 METAP2 (0.40) CRBNMAPTKIF11MEN1KMT2A
SCHEMBL27076383 0.83 MEN1 (0.39) CRBNMAPTKIF11MEN1KMT2A
SCHEMBL23188825 0.83 CRBN (0.39) CRBNMAPTKIF11MEN1KMT2A
SCHEMBL1318667 0.79 TGM2 (0.44) TGM2KIF11TDP2
SCHEMBL22469447 0.75 MAPT (0.53) CRBNMAPTKIF11NPC1SRD5A1
SCHEMBL27076399 0.74 KIF11 (0.33) CRBNMAPTKIF11
SCHEMBL2361634 0.72 PARP1 (0.33) TGM2MAPTMEN1KMT2ANPC1
SCHEMBL13726349 0.71 KIF11 (0.46) CRBNKIF11MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365695-B2 Fused ring heteroaryl compounds as RIPK1 inhibitors BISICHEM CO., LTD. (KR) 2025-07-22 — — US disclosed
CN-114206861-A Fused heteroaryl compounds useful as RIPK1 inhibitors 比西切姆有限公司 2022-03-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365695-B2 Fused ring heteroaryl compounds as RIPK1 inhibitors RIPK1, RIPK3, RIPK4 CRBN 4478/4885TGM2 3701/4885MAPT 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback